CClinicalTrials.gg
CompletedNCT05730543Updated Sep 7, 2023

Ethnic Lip Augmentation With Hyaluronic Acid Filler

A Phase 3 interventional study of Volbella or Juvederm Ultra XC filler in Lip Augmentation and Lip Fullness, sponsored by DeNova Research. Completed at 1 site in United States. Open to female participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by DeNova Research · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 5 months ago, and no results have been posted to the registry.
Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
21 Years and older
Sex
Female
01

Study summary

Lip augmentation using hyaluronic acid filler in females with Fitzpatrick skin type V-VI

Read the detailed description

Using the revised Allergan Lip Fullness Scale (LFS) to improve post injection patient satisfaction in women with Fitzpatrick skin type (FPST) 5 and 6 (examples: Hispanic, African descendants, Indigenous Australians).

02

Conditions studied

  • Lip Augmentation
  • Lip Fullness
03

In context

Lead sponsor

DeNova Research is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Females age 21 and above, with FPST 5 or 6, undergoing lip filler augmentation
  2. Subjects will be required not to have had previous lip filler, fat injections, or other lip treatments in the last 12 months.
  3. Subjects that understand the purpose and aspects of the study, freely sign the informed consent, complete the required treatment and follow up protocol.

Exclusion criteria

Exclusion Criteria:

  1. Females below the age of 21
  2. Male patients
  3. Subjects with LFS 5
  4. Fitzpatrick skin Type 1-4
  5. Subjects who have had previous lip filler, fat injections or other surgical lip augmentation in the last 12 months
  6. Subjects who are pregnant or nursing
  7. Subjects with a known allergy or sensitivity to any component of the study ingredients.
  8. Subjects that do not understand the purpose and aspects of the study, do not sign the consent, and do not complete the required treatment and follow up visit will also be excluded.
  9. Subjects with a history of bleeding disorders (Vitamin K deficiency, liver disease, renal disease, iatrogenic or otherwise). This includes persons who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks (such as Coumadin, Plavix, heparin analogues)
  10. Subjects should not be taking aspirin, nonsteroidal anti-inflammatory medications, St. John's Wort, or high doses of Vitamin E supplements within 7 days prior to the start of the study
  11. Subjects with active inflammation or infection in the area of treatment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Volbella or Juvederm Ultra XC filler

    Injection will not exceed a total of 4 cc of hyaluronic acid filler for combined treatment sessions (initial treatment + possible touch up treatment session).

    Drug: Volbella or Juvederm Ultra XC filler

Interventions

  • DrugVolbella or Juvederm Ultra XC filler

    Hyaluronic acid filler

06

What researchers measure

Primary outcomes

  1. Lip size

    The size of lip most desired based on the LFS scale. The possible choices are: 1) Minimal: flat or nearly flat contour, minimal red lip show. 2) Mild: some red lip show, no lower lip pout. 3) Moderate: Moderate red lip show with slight lower lip pout. 4) Marked: significant red lip show and lower lip pout, upper lip with moderate pout. 5) Very Marked: very significant red lip show, significant upper and lower lip pout.

    Time frame: 1 month

  2. Satisfaction level

    Satisfaction levels relative to baseline via the FACE-Q questionnaire. The questionnaire asks the following questions: 1) The shape of your lower lip? 2) How well your lips suit your face? 3) How nice your lips look when you smile. 4) How full your lower lip looks? 5) The style of your lips (e.g. pouty, natural)? 6) The shape of your upper lip? 7) How turned up your upper lip (cupids bow) looks? 8) The size of your lips? 9) How the outer corners of your lips look when your face is relaxed (still)? 10) How full your lips look? The possible choices for each question are as follows: very dissatisfied (1), somewhat dissatisfied (2), somewhat satisfied (3), very satisfied (4). Responses of very satisfied signify a more positive outcome. Overall scores closer to 40 signify a more favorable satisfaction level.

    Time frame: 1 month

Secondary outcomes

  1. LFS by age group

    LFS preference by age group (21-40 years old vs. 41+ years old). The size of lip most desired based on the LFS scale. The possible choices are: 1) Minimal: flat or nearly flat contour, minimal red lip show. 2) Mild: some red lip show, no lower lip pout. 3) Moderate: Moderate red lip show with slight lower lip pout. 4) Marked: significant red lip show and lower lip pout, upper lip with moderate pout. 5) Very Marked: very significant red lip show, significant upper and lower lip pout.

    Time frame: 1 month

  2. Improvement level

    Subjects will determine which LFS scale category they would like to be and then based upon final visit they will rate themselves again as to where they actually fall on the scale. Investigator will do the same but only at final visit.

    Time frame: 1 month

07

Study locations

1 site
  • DeNova Research
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Dayan SH, Bacos JT, Gandhi ND, Ho TT, Kalbag A. Assessment of the Impact of Perioral Rejuvenation With Hyaluronic Acid Filler on Projected First Impressions and Mood Perceptions. Dermatol Surg. 2019 Jan;45(1):99-107. doi: 10.1097/DSS.0000000000001613. PubMed 30059389 ↗
  • Werschler WP, Fagien S, Thomas J, Paradkar-Mitragotri D, Rotunda A, Beddingfield FC 3rd. Development and validation of a photographic scale for assessment of lip fullness. Aesthet Surg J. 2015 Mar;35(3):294-307. doi: 10.1093/asj/sju025. PubMed 25805282 ↗
  • Burgess C, Awosika O. Ethnic and Gender Considerations in the Use of Facial Injectables: African-American Patients. Plast Reconstr Surg. 2015 Nov;136(5 Suppl):28S-31S. doi: 10.1097/PRS.0000000000001813. PubMed 26441107 ↗

Individual participant data

Plan to share: No — Private study

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05730543
Lead sponsor
DeNova Research
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Nov 1, 2022
Primary completion
Apr 21, 2023
Completion
Jul 1, 2023
Last update
Sep 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion